2013-11-tom-johnson-all-india-research-team-anubhav-aggarwal.gif
Anubhav Aggarwal
Credit Suisse
First-place appearances: 1

Total appearances: 1

Analyst debut: 2013

Anubhav Aggarwal of Credit Suisse joins the lineup with a remarkable first-place finish. The researcher “explores often-ignored aspects of the health care industry and is highly articulate in communicating his views,” lauds one money manager. Aggarwal, 34, is more positive on the pharmaceuticals side of his sector than on hospitals, he reports, and especially prefers stocks with high exposure to U.S. markets. The opportunity there “is strong for Indian firms for the next decade at least,” he believes. On this basis, Sun Pharmaceutical Industries is among the analyst’s top picks. The Mumbai-based specialty pharma company manufactures and markets generics in the cardiology, diabetes, neurology and psychiatry segments for distribution in India, the U.S. and other markets. Upgraded from neutral to buy in May 2011, the stock had by mid-October 2013 skyrocketed an astounding 506 percent, on a split-adjusted basis, to 623.65 rupees — outperforming even the sector’s impressive 69.3 percent rise over that period. Upon earning an MBA from the Indian Institute of Management, Ahmedabad, Aggarwal joined Bank of America, where he spent two years before moving to Credit Suisse in 2008. — Katie Gilbert